Diamedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurological and kidney diseases, most notably through its lead product candidate DM199, a recombinant form of the human protein KLK1. The company generates revenue primarily through research grants and potential future licensing or commercialization of its therapies, as it does not yet have approved products on the market. Founded in Canada and now headquartered in Minnesota, DiaMedica has a history of advancing DM199 for conditions such as acute ischemic stroke and chronic kidney disease. Noteworthy for candidates is the company’s emphasis on clinical trial progress and regulatory milestones, which are central to its growth and future prospects. Understanding DiaMedica’s pipeline, strategic partnerships, and commitment to addressing unmet medical needs is essential for anyone considering a role at the company.

Recent Posts by Diamedica Therapeutics

1-1 of 1